Sanchorawala, Vaishali;
Boccadoro, Mario;
Gertz, Morie;
Hegenbart, Ute;
Kastritis, Efstathios;
Landau, Heather;
Mollee, Peter;
... Palladini, Giovanni; + view all
(2021)
Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines.
Amyloid
, 29
(1)
10.1080/13506129.2021.2002841.
Preview |
Text
Wechalekar_Guidelines for SCT for systemic AL amyloidosis.HL.pdf Download (366kB) | Preview |
Abstract
AL amyloidosis is a systemic amyloidosis and is associated with an underlying plasma cell dyscrasia. High dose intravenous melphalan and autologous stem cell transplantation was developed for the treatment of AL amyloidosis in the early 1990s and was prompted by its success in multiple myeloma. This application has evolved significantly over the past three decades. These guidelines provide a comprehensive assessment of eligibility criteria, stem cell collection and mobilisation strategies and regimens, risk-adapted melphalan dosing, role for induction and consolidation therapies, specific supportive care management, long-term outcome with respect to survival, haematologic response and relapse and organ responses following stem cell transplantation. These guidelines are developed by the experts in the field on behalf of the stem cell transplant working group of the International Society of Amyloidosis (ISA) and European Haematology Association (EHA).
| Type: | Article |
|---|---|
| Title: | Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines |
| Location: | England |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1080/13506129.2021.2002841 |
| Publisher version: | https://doi.org/10.1080/13506129.2021.2002841 |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
| Keywords: | Science & Technology, Life Sciences & Biomedicine, Biochemistry & Molecular Biology, Medicine, General & Internal, Medicine, Research & Experimental, General & Internal Medicine, Research & Experimental Medicine, AL amyloidosis, stem cell transplantation, melphalan, patient selection, supportive care, LIGHT-CHAIN AMYLOIDOSIS, INDUCTION THERAPY, MELPHALAN, BORTEZOMIB, BLOOD, PLERIXAFOR |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine > Inflammation |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10166045 |
Archive Staff Only
 |
View Item |
